Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602590 | 0.90 | NPC1 (0.40) | GAANPC1ATMRXFP1MAPT | |
| SCHEMBL3596576 | 0.89 | GAA (0.46) | GAANPC1ATMRXFP1FNTA | |
| Hydrochloric Acid SCHEMBL3601670 | 0.81 | MAPT (0.36) | GAANPC1ATMRXFP1MAPT | |
| SCHEMBL3595364 | 0.81 | NPC1 (0.46) | GAANPC1ATMRXFP1MAPT | |
| SCHEMBL3597910 | 0.79 | MAPT (0.47) | GAANPC1ATMRXFP1MAPT | |
| SCHEMBL3593134 | 0.77 | MAPT (0.40) | GAANPC1ATMRXFP1MAPT | |
| Hydrochloric Acid SCHEMBL3604363 | 0.77 | MAPT (0.39) | GAANPC1ATMRXFP1MAPT | |
| SCHEMBL3601464 | 0.77 | MAPT (0.47) | GAANPC1ATMRXFP1FNTA | |
| Hydrochloric Acid SCHEMBL3604763 | 0.75 | HPGD (0.34) | GAANPC1ATMRXFP1MAPT | |
| SCHEMBL3592666 | 0.75 | NPC1 (0.36) | GAANPC1ATMRXFP1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803811-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | US | disclosed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | disclosed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | FGFR3, FGFR1, NTRK3 | GAA 4090/4885NPC1 2040/4885ATM 3197/4885 |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | FGF2, FGF1, FGFR1 | GAA 2443/4885NPC1 2760/4885ATM 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.